Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22042645 | 0.86 | MAPK1 (0.33) | MAPK1ALDH1A1 | |
| SCHEMBL17082466 | 0.84 | MAPK1 (0.36) | MAPK1ALDH1A1TSHRTDP1 | |
| SCHEMBL212537 | 0.84 | MAPK1 (0.36) | MAPK1ALDH1A1TSHRTDP1 | |
| SCHEMBL453742 | 0.81 | — | — | |
| SCHEMBL8192630 | 0.78 | — | — | |
| SCHEMBL453741 | 0.78 | — | — | |
| SCHEMBL13423991 | 0.78 | — | — | |
| SCHEMBL8192633 | 0.78 | — | — | |
| SCHEMBL1142441 | 0.78 | — | — | |
| SCHEMBL6175846 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3543243-B1 | PROCESS FOR THE PREPARATION OF CUCURBITURIL DERIVATIVES | AQDOT LTD (GB) | 2022-02-02 | — | — | EP | claimed |
| US-10626119-B2 | Process for the preparation of cucurbituril and/or one or more derivatives thereof | AQDOT LIMITED (GB) | 2020-04-21 | — | — | US | claimed |
| EP-3543243-A1 | PROCESS FOR THE PREPARATION OF CUCURBITURIL DERIVATIVES | Aqdot Limited (GB) | 2019-09-25 | — | — | EP | claimed |
| US-20190241579-A1 | PROCESS FOR THE PREPARATION OF CUCURBITURIL AND/OR ONE OR MORE DERIVATIVES THEREOF | AQDOT LIMITED (GB) | 2019-08-08 | — | — | US | claimed |
| US-20180244681-A1 | PROCESS | AQDOT LIMITED (GB) | 2018-08-30 | — | — | US | claimed |
| WO-2018115822-A1 | PROCESS FOR THE PREPARATION OF CUCURBITURIL DERIVATIVES | AQDOT LIMITED (GB) | 2018-06-28 | — | — | WO | claimed |
| US-4374648-A | GASOLINE WITH DI-(T-BUTOXY)METHANE | CHEVRON RESEARCH COMPANY (US) | 1983-02-22 | — | — | US | claimed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| CN-118355020-A | Therapeutic compounds for HIV virus infection | 吉利德科学公司 | 2024-07-16 | — | — | CN | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-11873310-B2 | Compounds useful in HIV therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-01-16 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| EP-0485204-A2 | Process for the preparation of 3-alkoxymethyl cephalosporin derivatives | Sankyo Company Limited (JP) | 1992-05-13 | — | — | EP | disclosed |
| EP-0290551-A1 | COLD SETTING BINDING AGENT FOR MOULD MATERIALS AND APPLICATION THEREOF. | HUETTENES ALBERTUS (DE) | 1988-11-17 | — | — | EP | disclosed |
| WO-1988003847-A1 | COLD SETTING BINDING AGENT FOR MOULD MATERIALS AND APPLICATION THEREOF | Hüttenes-Albertus Chemische Werke GmbH (DE) | 1988-06-02 | — | — | WO | disclosed |
| EP-0268172-A1 | Cold setting mold material binder and its use | Hüttenes-Albertus Chemische-Werke GmbH (DE) | 1988-05-25 | — | — | EP | disclosed |
| US-4374648-A | GASOLINE WITH DI-(T-BUTOXY)METHANE | CHEVRON RESEARCH COMPANY (US) | 1983-02-22 | — | — | US | disclosed |
| US-4374648-A | GASOLINE WITH DI-(T-BUTOXY)METHANE | CHEVRON RESEARCH COMPANY (US) | 1983-02-22 | — | — | US | disclosed |
| US-4028424-A | FROM AN ALPHA-OLEFIN AND AN ALDEHYDE | JAPAN SYNTHETIC RUBBER CO., LTD. (JA) | 1977-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180244681-A1 | PROCESS | UCHL3, UCHL5, CBR3 | MAPK1 3545/4885ALDH1A1 80/4885TSHR 4166/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | MAPK1 772/4885ALDH1A1 2211/4885TSHR 3456/4885 |
| US-11873310-B2 | Compounds useful in HIV therapy | CD4, CCR5, ABCB1 | MAPK1 3593/4885ALDH1A1 424/4885TSHR 4870/4885 |
| US-10626119-B2 | Process for the preparation of cucurbituril and/or one or more derivatives thereof | UCHL3, UCHL1, UCHL5 | MAPK1 2982/4885ALDH1A1 98/4885TSHR 3492/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | MAPK1 4161/4885ALDH1A1 3688/4885TSHR 3794/4885 |
| US-20190241579-A1 | PROCESS FOR THE PREPARATION OF CUCURBITURIL AND/OR ONE OR MORE DERIVATIVES THEREOF | UCHL3, UCHL1, UCHL5 | MAPK1 2982/4885ALDH1A1 98/4885TSHR 3492/4885 |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | CRBN, MDM2, UBE2N | MAPK1 3128/4885ALDH1A1 3412/4885TSHR 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.